This site is intended for Healthcare Professionals only
Back to CKS

Gastrointestinal Infections and infestations

Diarrhoea - adult's assessment

Last revised in November 2023

Diarrhoea is the abnormal passing of loose or liquid stools, with increased frequency and/or increased volume.

Diarrhoea - adult's assessment: Summary

  • Diarrhoea is the passage of three or more loose or liquid stools per day (or more frequently than is normal for the individual).
    • Acute diarrhoea is defined as lasting less than 14 days.
    • Persistent diarrhoea is defined as lasting more than 14 days.
    • Chronic diarrhoea is defined as lasting for more than 4 weeks.
  • Acute diarrhoea is usually caused by a bacterial or viral infection. Other causes include medication, anxiety, food allergy, and acute appendicitis.
  • Causes of chronic diarrhoea include irritable bowel syndrome, diet, inflammatory bowel disease, coeliac disease, and bowel cancer.
  • Diarrhoea is one of the most common symptoms for which people seek medical advice.
  • Assessment for acute and chronic diarrhoea should include:
    • Determining onset, duration, frequency, and severity of symptoms.
    • Identifying red flag symptoms.
    • Ascertaining the underlying cause.
    • Looking for complications, such as dehydration.
  • Acute diarrhoea should be investigated with a stool specimen for routine microbiology investigation under certain circumstances, including if:
    • The person is systemically unwell; and needs hospital admission and/or antibiotics.
    • There is blood or pus in the stool.
    • The person is immunocompromised.
    • The person has recently received antibiotics, a proton pump inhibitor (PPI) or been in hospital (specific testing for Clostridium difficile should also be requested). 
    • Diarrhoea occurs after foreign travel (tests for ova, cysts, and parasites should also be requested).
    • Amoebae, Giardia, or cryptosporidium are suspected, particularly if diarrhoea is persistent (14 days or more) or the person has travelled to an at-risk area.
    • There is a need to exclude infectious diarrhoea. 
  • Investigations for chronic diarrhoea should be tailored to the individual, but blood tests should be requested in all people presenting with this problem. These include full blood count, urea and electrolytes, liver function tests, calcium, vitamin B12 and red blood cell folate, ferritin, thyroid function tests, ESR and CRP, and testing for coeliac disease.
  • People with diarrhoea may require admission to hospital, referral using a suspected cancer pathway, or routine referral for further assessment and management depending on their presentation and the certainty of the diagnosis.

Have I got the right topic?

From age 18 years onwards.

This CKS topic covers the assessment of acute and chronic diarrhoea in adults.

This CKS topic does not cover the assessment of diarrhoea in children, or the management of diarrhoea. This CKS topic also does not cover the assessment of post-operative diarrhoea, or diarrhoea associated with a stoma.

There are separate CKS topics on Bowel screening, Coeliac disease, Constipation, Crohn's disease, Diarrhoea - antibiotic associated, Diverticular disease, Gastroenteritis, Gastrointestinal tract (lower) cancers - recognition and referral, Irritable bowel syndrome, and Ulcerative colitis. 

The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.

How up-to-date is this topic?

Changes

November 2023 — reviewed. A literature search was conducted in October 2023 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. There are no changes to the recommendations.

Previous changes

June 2023 — minor update. A recommendation to ask about sexual history, particularly in men who have sex with men, has been added to this topic in line with the British Association of Sexual Health and HIV (BASHH) United Kingdom national guideline for the management of sexually transmitted enteric infections 2023.

May 2021 — minor update. Information that unexplained chronic diarrhoea is an HIV indicator condition has been added to this topic in line with the British HIV Association/British Association for Sexual Health and HIV/British Infection Association Adult HIV testing guidelines 2020.

December 2018 — reviewed. A literature search was conducted in September 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. New recommendations have been added to the referral section, reflecting the National Institute for Health and Care Excellence guideline on Suspected cancer: recognition and referral [NICE, 2015a]. In the scenario on chronic diarrhoea, there have been changes to the assessment section and new tests to consider have been added to the recommendations on investigations.

March 2013 — reviewed. A literature search was conducted in February 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. There are no changes to the recommendations.

September to December 2010 — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.

Update

New evidence

Evidence-based guidelines

No new evidence-based guidelines since 1 November 2023.

HTAs (Health Technology Assessments)

No new HTAs since 1 November 2023.

Economic appraisals

No new economic appraisals relevant to England since 1 November 2023.

Systematic reviews and meta-analyses

No new systematic review or meta-analysis since 1 November 2023.

Primary evidence

No new primary evidence which reaches the CKS threshold for inclusion published since 1 November 2023.

New policies

No new national policies or guidelines since 1 November 2023.

New safety alerts

No new safety alerts since 1 November 2023.

Changes in product availability

No changes in product availability since 1 November 2023.

Goals and outcome measures

Goals

To support primary healthcare professionals to:

  • Assess the symptoms of diarrhoea and diagnose an underlying cause where possible in primary care.
  • Refer people with appropriate urgency for further investigation or treatment.

Outcome measures

No outcome measures were found during the review of this topic.

Audit criteria

No audit criteria were found during the review of this topic.

QOF indicators

No QOF indicators were found during the review of this topic.

QIPP - Options for local implementation

No QIPP indicators were found during the review of this topic.

NICE quality standards

  • People at increased risk or with symptoms of coeliac disease are offered a serological test for coeliac disease.
  • Adults with symptoms of irritable bowel syndrome are offered tests for inflammatory markers as first‑line investigation to exclude inflammatory causes.
  • Adults presenting in primary care with symptoms that suggest colorectal cancer, who do not meet the referral pathway criteria, have a test for blood in their faeces.

[NICE, 2016a; NICE, 2016b; NICE, 2016c]

Background information

What is it?

  • Diarrhoea is a symptom, of which there are many causes.
  • Many different definitions of diarrhoea have been suggested, but the World Health Organization defines diarrhoea as 'the passage of three or more loose or liquid stools per day (or more frequent passage than is normal for the individual)' [WHO, 2017]. 

What is the pathophysiology of diarrhoea?

  • Mechanisms that can cause diarrhoea are  
    • Increased osmotic load in the gut lumen.
      • Osmotic diarrhoea occurs when a soluble compound cannot be absorbed by the small intestine and thus draws fluid into the intestinal lumen. Examples include osmotic laxatives; magnesium-based antacids; and foods containing mannitol, sorbitol, or xylitol. Osmotic diarrhoea can also be due to generalised malabsorption (for example, coeliac disease and pancreatic insufficiency). 
      • Osmotic diarrhoea will stop if the person fasts.
    • Increase in secretion.
      • Secretory diarrhoea results from increased secretion of fluid and electrolytes into the intestine with decreased absorption. Infections with such organisms as Vibrio cholerae, Escherichia coli, and Clostridioides difficile can cause secretory diarrhoea, as can bile salts in the colon (for example, after ileal resection), some drugs (for example, laxatives, diuretics, theophylline, cholinergic drugs, prostaglandins, caffeine, and ethanol) and gut allergies.
      • Even if a person fasts, secretory diarrhoea will persist.
    • Inflammation of the intestinal lining.
      • Damage to intestinal mucosal cells affects the absorption of fluid and electrolytes and results in fluid and blood loss. Infection (for example Shigella) and conditions such as ulcerative colitis and Crohn's disease are causes of inflammatory diarrhoea.
      • Nocturnal symptoms are often present.
    • Increased intestinal motility.
      • This may present with an increased frequency of stool passage without an increase in volume. It can occur with endocrine conditions such as diabetes and hyperthyroidism.
  • More than one mechanism may cause diarrhoea in an affected person.

What causes it?

What causes acute diarrhoea?

  • Worldwide, acute diarrhoea is most commonly caused by infection [BMJ Best Practice, 2023a]. 
    • Viruses are the most common infectious cause in the community.
      • Among people who consult their GP, norovirus is one of the most common organisms isolated, as well as sapovirus and rotavirus [Tam, 2012a]. Norovirus is the most common cause of sporadic outbreaks of gastroenteritis affecting all age groups [GBD, 2018].
    • Bacterial causes include infection with Salmonella species, Campylobacter jejuni, Shigella species, and Escherichia coli [UKHSA, 2023]. 
      • Campylobacter jejuni is one of the most common organisms isolated among people who consult their GP [Tam, 2012b]. 
      • Clostridioides difficile can cause infectious diarrhoea in people who have taken antibiotics, especially those who are older, immunocompromised, or have been in hospital [GBD, 2018]. For more information, see the CKS topic on Diarrhoea - antibiotic associated.
    • Parasitic causes are the most common infections causing persistent diarrhoea. Protozoa are important and include Cryptosporidium, Giardia, Entamoeba histolytica, and Cyclospora. Protozoan and bacterial infections may cause persistent diarrhoea (duration of 14 days or more). 
    • Infections that can present with bloody diarrhoea include [BMJ Best Practice, 2023a]: 
      • Bacterial: Campylobacter jejuni, Salmonella, Escherichia coli O157:H7, Vibrio parahaemolyticus, Shigella, Yersinia, Aeromonas, Clostridioides difficile.
      • Viruses: cytomegalovirus.
      • Parasites: Entamoeba histolytica, schistosomiasis.
    • For more information on infectious causes, see the CKS topic on Gastroenteritis.
  • Drugs associated with diarrhoea include laxatives, allopurinol, angiotensin-II receptor blockers, antibiotics, chemotherapy, magnesium-containing antacids, metformin, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and selective serotonin reuptake inhibitors [Arasaradnam, 2018].  
    • For more information on specific drugs and whether diarrhoea is a reported adverse effect, see the manufacturer's Summary of Product Characteristics at www.medicines.org.uk/emc.
  • Other causes of acute diarrhoea include [BMJ Best Practice, 2023a]: 
    • Anxiety.
    • Food allergy. 
    • Acute appendicitis.
    • Pelvic radiation treatment.
    • Intestinal ischaemia.
    • Early presentation of a chronic cause (for example, a first presentation of inflammatory bowel disease).

What causes chronic diarrhoea?

  • Chronic diarrhoea has a broader differential diagnosis than acute diarrhoea. More common causes of chronic diarrhoea include [Arasaradnam, 2018]: 
    • Irritable bowel syndrome 
      • Irritable bowel syndrome is a functional disorder of the bowel. It is characterized by frequent episodes of bowel disturbance, abdominal discomfort or pain, and bloating, which may affect daily activities. Diet or stress may exacerbate symptoms. The cause is unclear, but there may be an association with increased bowel sensitivity or abnormal muscle activity in the bowel wall [NICE, 2017]. Associated symptoms include headache, back pain, and psychosocial distress. 
      • For more information, see the CKS topic on Irritable bowel syndrome.
    • Diet 
      • For example, fermentable oligo-, di-, mono-saccharides and polyols (FODMAP) malabsorption, artificial sweeteners such as sorbitol, caffeine, and excess alcohol [Arasaradnam, 2018]. 
    • Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
    • Microscopic colitis 
      • Microscopic colitis is a clinicopathological diagnosis that causes chronic watery diarrhoea, especially in older women. Other symptoms may be non-specific but include abdominal pain, weight loss and arthralgia [Gentile, 2018].
    • Coeliac disease
      • Coeliac disease is a common autoimmune disorder in which there is a heightened immunological response to gluten. Coeliac disease can present in adulthood (fourth or fifth decade) with symptoms including abdominal pain, change in bowel habits, and anaemia, although people with the condition do not always have abdominal symptoms or signs of malabsorption. For more information, see the CKS topic on Coeliac disease.
    • Other causes of malabsorption
      • These include lactose intolerance and pancreatic insufficiency.  
    • Colorectal cancer
    • Bile acid diarrhoea
      • Bile acid diarrhoea is due to imbalances in bile acid homeostasis in the enterohepatic circulation and may occur as a result of ileal disease or dysfunction (such as Crohn's disease or terminal ileum resection) or be idiopathic. Excess bile acid in the colon causes diarrhoea through effects on electrolyte balance and speeding up of large bowel transit time [Hughes, 2021]. 
    • Drugs
      • Examples include antibiotics (particularly macrolides such as erythromycin), antihypertensives (for example, ACE inhibitors), nonsteroidal anti-inflammatory drugs, hypoglycaemic drugs (such as metformin and gliptins), magnesium-containing products, proton pump inhibitors, selective serotonin reuptake inhibitors, antineoplastic drugs, theophyllines, antiarrhythmics, and furosemide  [Arasaradnam, 2018].  
      • For more information on specific drugs and whether diarrhoea is a reported adverse effect, see the manufacturer's Summary of Product Characteristics at www.medicines.org.uk/emc.
    • Constipation and faecal impaction (leading to overflow) [Arasaradnam, 2018].  
      • This is common in frail older people.  
  • Other less common diagnoses to consider include [Arasaradnam, 2018]:
    • Infection — it is unusual for chronic diarrhoea to be caused by an infection in an immunocompetent person, although chronic infections can result from protozoan infections (for example, giardiasis and amoebiasis). 
    • HIV infection — unexplained chronic diarrhoea is an HIV indicator condition [John, 2021]. For more information, see the CKS topic on HIV infection and AIDS.  
    • Small bowel bacterial overgrowth.
    • Mesenteric ischaemia.
    • Lymphoma.
    • Surgical causes (for example, small bowel resection, internal fistulae).
    • Chronic pancreatitis, pancreatic carcinoma.
    • Radiation enteropathy.
    • Endocrine disorders — for example, hyperthyroidism, diabetes (may be metformin-associated), hypoparathyroidism, Addison’s disease.
    • Cystic fibrosis.
    • Factitious diarrhoea — the person adds water to their stools or uses laxatives. 
    • Small bowel enteropathy (for example, Whipple’s disease, tropical sprue, amyloid).
    • Hormone-secreting tumours (for example, VIPoma, gastrinoma, carcinoid).
    • Autonomic neuropathy.
    • Brainerd diarrhoea (possibly due to an infectious cause, but not identified).

How common is it?

  • Diarrhoea is one of the most common symptoms for which people seek medical attention. 
    • For prevalence data for a specific condition, see the relevant CKS topic.
  • Acute diarrhoea
    • Infectious diarrhoea is common [Nemeth, 2022]. 
    • A prospective cohort study conducted in the UK has estimated that there are up to 17 million cases and 1 million GP consultations attributed to acute infectious diarrhoea every year [Tam, 2012a]. 
      • The most commonly isolated pathogens in the community presenting to primary care were norovirus, sapovirus, Campylobacter spp. and rotavirus. Clostridioides difficile associated diarrhoea was rarely reported.
  • Chronic diarrhoea
    • Chronic diarrhoea is a common reason for referral to gastroenterology, but its prevalence is difficult to estimate because definitions of chronic diarrhoea vary [Arasaradnam, 2018]. It is estimated to affect 5% of the population at any given time [Descoteaux-Friday, 2023].

What are the complications?

  • In developed countries, diarrhoea is an important cause of morbidity, but it is responsible for relatively few deaths [GBD, 2018]. 
    • Dehydration increases the risk of life-threatening illness and death, particularly in young infants, children, and older people, and in developing countries [Nemeth, 2022; BMJ Best Practice, 2023a]. 
  • Chronic diarrhoea can negatively impact quality of life; for example, avoidance of travelling or going to new places where access to toilet facilities may be difficult, but the main physical consequence is malabsorption [Descoteaux-Friday, 2023]. 
  • For information on the complications occurring as a result of specific infections causing diarrhoea, see the CKS topic on Gastroenteritis.  
  • For complications of conditions causing diarrhoea, see the appropriate CKS topic, for example, Coeliac disease, Crohn's disease, and Ulcerative colitis.  

What is the prognosis?

  • Most infectious diarrhoea is of viral origin and is self-limiting, with nearly half of episodes lasting less than a day [BMJ Best Practice, 2023a; Ferris, 2023].  
  • It is thought that:  
    • Viral diarrhoea lasts around 2–3 days.
    • Untreated bacterial diarrhoea has a duration of around 3–7 days.
    • Protozoal diarrhoea can be present for weeks to months without treatment.
  • The prognosis of chronic diarrhoea will depend on the underlying cause.

Management

Scenario: Acute diarrhoea (less than 4 weeks)

From age 18 years onwards.

How should I assess a person with acute diarrhoea?

  • Determine the onset, duration, frequency, and severity of symptoms.
    • The onset of symptoms within 6 hours of contaminated food suggests a pre-formed toxin of either Bacillus cereus or Staphylococcus aureus as the cause.
    • More frequent stool passage suggests an infectious cause.
    • Watery stools are associated with non-invasive and toxin-producing pathogens.
  • Enquire about the presence of red flag symptoms:
    • Blood in the stool, which is usually seen with invasive pathogens or severe inflammation, e.g. ulcerative colitis.
    • Recent hospital treatment or antibiotic treatment. For more information, see the CKS topic on Diarrhoea - antibiotic associated.
    • Weight loss.
    • Evidence of dehydration.
    • Nocturnal symptoms — organic cause more likely.
  • Also ask about sexual history (particularly in men who have sex with men) to exclude sexually transmitted enteric infection. 
  • Attempt to ascertain the underlying cause. Assess for:
    • Quantity and character of stools (watery, fatty, containing blood or mucus).
    • Features suggesting infection, such as:
      • Fever — often seen with invasive pathogens e.g. Salmonella, Shigella, and Campylobacter, enteric viruses or a cytotoxic organism such as Clostridioides difficile.
      • Vomiting.
      • Recent contact with a person with diarrhoea.
      • Exposure to possible sources of enteric infection (for example certain foodstuffs such as meat, shellfish, dairy, and eggs), having eaten meals out, or recent farm or petting zoo visits).
      • Travel abroad — increases the likelihood of infection. Ask about potential exposures such as raw milk or untreated water.
      • Being in a higher risk group such as food handlers, nursing home residents (greater risk of norovirus, Cryptosporidium, and Giardia), and recently hospitalized people.
    • Any new drugs, especially antibiotics or laxatives. For examples, see the Causes section on Acute diarrhoea.
    • Stress or anxiety.
    • Abdominal pain, which is often present in inflammatory bowel disease, irritable bowel syndrome, and ischaemic colitis.
    • History of recent radiation treatment to the pelvis.
    • Factors increasing the risk of immunosuppression (for example, human immunodeficiency virus infection, long-term steroid use, or chemotherapy).
    • Any surgery or medical conditions (for example, endocrine disease) accounting for the diarrhoea. 
    • Diet and use of alcohol or substances such as sorbitol.
  • Assess for complications of diarrhoea, such as dehydration.
    • Features indicating dehydration include increased pulse rate, reduced skin turgor, dryness of mucous membranes, delayed capillary refill time, decreased urine output, hypotension (check for postural changes), and altered mental status. For more detail, see Clinical features of dehydration.
    • Also consider underlying conditions that may increase the risk of complications.
  • Perform an abdominal examination to assess for pain or tenderness, distension, mass, increased or decreased bowel sounds, or liver enlargement.
  • Consider a rectal examination to assess for rectal tenderness, stool consistency, blood, mucus, and possible malignancy.
  • If acute causes have been excluded and the person has features suggestive of an early presentation of a chronic cause, see Scenario: Chronic diarrhoea (more than 4 weeks).

Clinical features of dehydration

The following signs are observed in dehydration:

  • Mild dehydration:
    • Lassitude.
    • Anorexia, nausea.
    • Light-headedness.
    • Postural hypotension.
    • Usually no signs.
  • Moderate dehydration:
    • Apathy/tiredness.
    • Dizziness.
    • Nausea/headache.
    • Muscle cramps.
    • Pinched face.
    • Dry tongue or sunken eyes.
    • Reduced skin elasticity.
    • Postural hypotension.
    • Tachycardia.
    • Oliguria.
  • Severe dehydration:
    • Profound apathy.
    • Weakness.
    • Confusion, leading to coma.
    • Shock.
    • Tachycardia.
    • Marked peripheral vasoconstriction.
    • Systolic blood pressure less than 90 mmHg.
    • Oliguria or anuria.

However, these signs and symptoms have been shown to have poor diagnostic accuracy (particularly in the elderly). Plasma or serum osmolality measurement is the gold standard for diagnosis, with a 90% sensitivity and 100% specificity for plasma osmolality.

[Bunn, 2019; Lacey, 2019]

Basis for recommendation

These recommendations are based on the 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea  [Shane, 2017], the Centers for Disease Control Yellow book Travelers' Diarrhea [CDC, 2023], the BMJ Best Practice guide Assessment of acute diarrhoea [BMJ Best Practice, 2023a], and the review articles Diarrhea [Nemeth, 2022] and Bacterial Diarrhea [Akhondi, 2023].  

How should I investigate acute diarrhoea in primary care?

  • Send a faecal specimen for routine microbiology investigation if a person with diarrhoea has:
    • Symptoms/signs or a clinical indication:
      • The person is systemically unwell; needs hospital admission and/or antibiotics.
      • There is blood or pus in the stool.
      • The person is immunocompromised.
      • The person has recently received antibiotics, a proton pump inhibitor (PPI) or been in hospital — also request specific testing for Clostridioides difficile. For more information, see the CKS topic on Diarrhoea - antibiotic associated. 
      • Diarrhoea occurs after foreign travel — also request tests for ova, cysts, and parasites and state the countries visited on the form.
      • Amoebae, Giardia, or cryptosporidium are suspected, particularly if diarrhoea is persistent (2 weeks or more) or the person has travelled to an at-risk area.
      • There is a need to exclude infectious diarrhoea (for example, severe abdominal pain, exacerbation of inflammatory bowel disease, or irritable bowel syndrome).
    • A public health indication:
      • Diarrhoea in high-risk people (for example food handlers, healthcare workers, elderly residents in care homes).
      • Suspected food poisoning (for example after a barbeque or restaurant meal or eating eggs, chicken, or shellfish).
      • Outbreaks of diarrhoea in the family or community, when isolating the organism, may help pinpoint the source of the outbreak.
      • Contacts of people infected with certain organisms, for example, Escherichia coli O157 or C. difficile, where there may be serious clinical sequelae to an infection.
      • Close household contacts of a person with a Giardia infection.
  • For more information on how to send a stool sample (such as what information to include), see Sending a stool sample.
  • Consider blood tests if infection and the other causes of acute diarrhoea have been excluded and it is suspected that an episode of acute diarrhoea is due to a chronic cause.

Sending a stool sample

  • Send a single specimen (a quarter-full specimen pot is the minimum needed for routine microbiology investigation). Only send loose stools, as the laboratory will not examine formed stools. 
  • If diarrhoea occurs after exotic travel abroad, is recurrent, or prolonged, request ova, cysts, and parasites and give details of travel. Send three specimens a minimum of 2 days apart (ova, cysts, and parasites are shed intermittently).
  • Ensure that the following details are included on the request form:
    • Clinical features (for example, fever; bloody stool; severe abdominal pain).
    • History of immunosuppression.
    • Food intake (for example, shellfish).
    • Recent foreign travel (specify countries).
    • Recent antibiotic therapy, proton pump inhibitor therapy, or hospitalization (suggestive of Clostridioides difficile infection).
    • Exposure to untreated water (suggestive of infection with protozoa).
    • Contact with other affected people or an outbreak.
  • Repeat specimens are usually unnecessary unless advised by a specialist (microbiologist or consultant in public health), or ova, cysts and parasites are suspected.

Basis for recommendation

  • These recommendations are largely based on and extrapolated from UK Health Security Agency (UKHSA) guidance Managing specific infectious diseases (gastroenteritis chapter) [UKHSA, 2023], the BMJ Best Practice guide Assessment of acute diarrhoea [BMJ Best Practice, 2023a], the review articles Diarrhea [Nemeth, 2022] and Bacterial Diarrhea [Akhondi, 2023]. 
Considering blood tests
  • This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. 

When should I admit or refer a person with acute diarrhoea?

  • Arrange emergency admission to hospital if:
    • The person is vomiting and unable to retain oral fluids, or
    • They have features of severe dehydration or shock (for more information, see Clinical features of dehydration).
  • Other factors that influence the threshold for admission include (use clinical judgment):
    • Older age (people 60 years of age or older are more at risk of complications).
    • Home circumstances and level of support.
    • Fever.
    • Bloody diarrhoea.
    • Abdominal pain and tenderness.
    • Increased risk of poor outcome, for example:
      • Coexisting medical conditions — immunodeficiency, lack of stomach acid, inflammatory bowel disease, valvular heart disease, diabetes mellitus, renal impairment, rheumatoid disease, systemic lupus erythematosus.
      • Drugs — immunosuppressants or systemic steroids, proton pump inhibitors, angiotensin-converting enzyme inhibitors, diuretics.
  • Refer adults using a suspected cancer pathway referral (adult to receive a diagnosis or ruling out of cancer within 4 weeks of urgent referral from GP) for colorectal cancer if:
    • They have a positive quantitative faecal immunochemical test (FIT), which has been requested because:
      • They are aged 40 and over with unexplained weight loss and abdominal pain, or
      • They are aged 50 and over with unexplained rectal bleeding, or
      • They are aged 60 and over with iron deficiency anaemia or changes in their bowel habit, or tests show occult blood in their faeces.
  • Consider a suspected cancer pathway referral (adult to receive a diagnosis, or ruling out of cancer within 4 weeks of urgent referral from GP) where: 
    • Adults have a positive quantitative faecal immunochemical test (FIT), which has been requested because:
      • Adults have a rectal or abdominal mass.
      • Adults aged under 50 with rectal bleeding and any of the following unexplained symptoms or findings:
        • Abdominal pain.
        • Change in bowel habits.
        • Weight loss.
        • Iron-deficiency anaemia.
  • Refer if the diagnosis remains uncertain after a primary care assessment — if infection and the other common causes of acute diarrhoea have been excluded and it is suspected that an episode of acute diarrhoea is due to a chronic cause. 

Basis for recommendation

These recommendations are extrapolated from an expert consensus guideline The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection [Farthing, 1996], the BMJ Best Practice guide Assessment of acute diarrhoea [BMJ Best Practice, 2023a] and the National Institute for Health and Care Excellence guideline Suspected cancer: recognition and referral [NICE, 2023]. 

Referral if the diagnosis remains uncertain
  • CKS has based this recommendation on what it considers to be good clinical practice.

Scenario: Chronic diarrhoea (> 4 weeks)

From age 18 years onwards.

How should I assess a person with chronic diarrhoea?

  • Determine the duration, frequency, pattern, and severity of symptoms.
  • Ask about and look for red flag indicators (symptoms and/or features that may be caused by another condition that needs referral or further investigation). These include: 
    • Unexplained weight loss.
    • Unexplained rectal bleeding.
    • Persistent blood in the stool.
    • Abdominal mass.
    • Rectal mass.
    • Severe abdominal pain.
    • Iron deficiency anaemia.
    • Raised inflammatory markers (may indicate inflammatory bowel disease).
    • Nocturnal or continuous diarrhoea or both (suggestive of an organic rather than functional disorder).
    • Fever, tachycardia, hypotension, dehydration.
  • Look for other features suggestive of an underlying cause, including:
    • Travel abroad — consider an infective cause, especially Giardia.
    • Laxative use (including for treatment of hepatic encephalopathy).
    • Other drugs. For examples, see the section on chronic causes of diarrhoea.
      • Recent use of an antibiotic or proton pump inhibitor is associated with Clostridioides difficile infection.
    • Chronic fatty diarrhoea — suggests fat maldigestion (for example pancreatic insufficiency) or fat malabsorption (for example coeliac disease).
    • Previous abdominal surgery — suspect bile acid diarrhoea if the person has a history of cholecystectomy or ileal resection.
    • Family history of coeliac disease or inflammatory bowel disease.
    • Diet and relationship of symptoms to eating — lactose intolerance is suggested if symptoms are worsened by dairy products; diarrhoea may be due to consumption of caffeine or food additives, such as sorbitol.
    • Excessive alcohol intake — can cause a toxic effect on intestinal epithelium or rapid gut transit.
    • Abdominal pain — may indicate coeliac disease, Crohn's disease, or malignancy.
    • Weight loss, anxiety, palpitations, tremors — consider hyperthyroidism.
    • Lifelong history of constipation — consider impaction with overflow diarrhoea.
    • Immunocompromised person — consider opportunistic infection with parasites (for example Giardia, Cryptosporidium, and Cyclospora).
    • Features of systemic disease (such as thyrotoxicosis, diabetes, adrenal insufficiency).
    • Systemic illness affecting gastrointestinal motility (for example scleroderma, diabetes mellitus); history of inflammatory bowel disease; previous gastrointestinal surgery with risk of stricture — consider small intestinal bacterial overgrowth (SIBO).
    • Rashes (for example pyoderma gangrenosum or erythema nodosum in inflammatory bowel disease; hyperpigmentation in Addison's disease; and dermatitis herpetiformis in coeliac disease).
  • Assess for features that indicate a diagnosis of irritable bowel syndrome.
  • Perform an abdominal examination, looking for distension, an abdominal mass, organomegaly, or tenderness.
  • Perform a digital rectal examination, provided this is acceptable to the person being examined. Note any faecal leakage, haemorrhoids, type of stool, and presence of blood.

Basis for recommendation

These recommendations are based on the BMJ Best Practice guide Assessment of chronic diarrhoea [BMJ Best Practice, 2023b], National Institute for Health and Care Excellence (NICE) guideline on Irritable bowel syndrome [NICE, 2017] and referral criteria in the NICE guideline Suspected cancer: recognition and referral [NICE, 2023].

Identifying red flag symptoms

How should I investigate chronic diarrhoea in primary care?

Tailor investigations to the individual, and if necessary, refer for further investigation.

  • Request the following blood tests in all people with chronic diarrhoea:
    • Full blood count — to detect anaemia.
    • Urea and electrolytes.
    • Liver function tests, including albumin level.
    • Calcium.
    • Vitamin B12 and red blood cell folate.
    • Iron status (ferritin).
    • Thyroid function tests.
    • ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein). 
    • Testing for coeliac disease — immunoglobulin A (IgA), and IgA tissue transglutaminase (tTG), or IgA endomysial antibody (EMA).
      • Note that antibodies usually will become negative when a person is on a gluten-free diet, so the test should be carried out when they are eating a diet containing gluten.
      • For more information, see the CKS topic on Coeliac disease. 
  • Consider CA125 testing if there are symptoms suggestive of ovarian cancer. For more information, see the CKS topic on Ovarian cancer.
  • Consider HIV serology if underlying immunodeficiency is suspected. For more information, see the CKS topic on HIV infection and AIDS. 
  • Consider sending stool for:
    • Routine microbiology investigation and examination for ova, cysts and parasites, if an infectious cause is suspected or there is a history of exotic foreign travel.
    • Clostridium difficile testing, particularly if the person has recently been admitted to hospital or treated with antibiotics or a proton pump inhibitor, or if a previous episode has resolved and the symptoms have recurred. For more information, see the CKS topic on Diarrhoea - antibiotic associated.
    • Faecal calprotectin testing to help differentiate between irritable bowel syndrome and inflammatory bowel disease in people under the age of 40 years if specialist assessment is being considered and cancer is not suspected. 
      • Note that faecal calprotectin should not be used for people:
        • With new onset rectal bleeding or bloody diarrhoea.
        • In whom there is a need to rule out cancer. 
      • For more information, see the CKS topics on Crohn's disease and Ulcerative colitis. 
    • Testing for blood in the faeces in people with symptoms suggestive of colorectal cancer who do not meet suspected cancer referral pathway criteria.

Basis for recommendation

These recommendations are based on Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology [Arasaradnam, 2018], Irritable bowel syndrome in adults: diagnosis and management [NICE, 2017], Coeliac disease: recognition, assessment and management [NICE, 2015b], BSG guidance document on use of faecal calprotectin [BSG, 2016], Suspected cancer: recognition and referral [NICE, 2023], the review articles Chronic diarrhoea [John, 2021],  Bile acid diarrhoea: Current and potential methods of diagnosis [Hughes, 2021], Investigating young adults with chronic diarrhoea in primary care [Chapman, 2015] and Chronic Diarrhea [Descoteaux-Friday, 2023].

When should I refer a person with chronic diarrhoea?

  • Refer adults using a suspected cancer pathway referral (adult to receive a diagnosis or ruling out of cancer within 4 weeks of urgent referral from GP) for colorectal cancer if:
    • They are aged 40 and over with unexplained weight loss and abdominal pain, or
    • They are aged 50 and over with unexplained rectal bleeding, or
    • They are aged 60 and over with iron deficiency anaemia or changes in their bowel habit, or tests show occult blood in their faeces.
  • Consider a suspected cancer pathway referral (adult to receive a diagnosis, or ruling out of cancer within 4 weeks of urgent referral from GP) for colorectal cancer in: 
    • Adults with a rectal or abdominal mass.
    • Adults aged under 50 with rectal bleeding and any of the following unexplained symptoms or findings:
      • Abdominal pain.
      • Change in bowel habits.
      • Weight loss.
      • Iron-deficiency anaemia.
  • Refer for further assessment and management if:
    • History, examination, and blood test results suggest any of the following:
      • Coeliac disease. For more information, see the CKS topic on Coeliac disease.
      • Crohn's disease. For more information, see the CKS topic on Crohn's disease. 
      • Ulcerative colitis. For more information, see the CKS topic on Ulcerative colitis. 
      • Bile acid diarrhoea. 
      • Microscopic colitis.
      • Malabsorption.
    • A person less than 40 years of age does not have typical symptoms of functional bowel disorder and/or has severe symptoms and documented diarrhoea. 
    • The diagnosis is uncertain. 

Basis for recommendation

These recommendations are based on Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology [Arasaradnam, 2018], Coeliac disease: recognition, assessment and management [NICE, 2015b], Suspected cancer: recognition and referral [NICE, 2023], and the BMJ Best Practice guide Assessment of chronic diarrhoea [BMJ Best Practice, 2023b].

Supporting evidence

This CKS topic is based on the British Society of Gastroenterology Guidelines for the investigation of chronic diarrhoea in adults [Arasaradnam, 2018], the National Institute for Health and Care Excellence guideline Suspected cancer: recognition and referral [NICE, 2023], and the 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea [Shane, 2017], expert opinion in review articles Diarrhea [Nemeth, 2022] and Chronic Diarrhea [Descoteaux-Friday, 2023], and the BMJ Best Practice guides Assessment of chronic diarrhoea [BMJ Best Practice, 2023b] and Assessment of acute diarrhoea [BMJ Best Practice, 2023a]. The rationale for the diagnosis, primary care assessment, and referral of adults with diarrhoea is outlined in the relevant basis for recommendation sections of the topic.

How this topic was developed

This section briefly describes the processes used in developing and updating this topic. Further details on the full process can be found in the About Us section and on the Clarity Informatics website.

Search strategy

A literature search was conducted for guidelines and systematic reviews on primary care assessment of diarrhoea.

Search dates

September 2018 - October 2023

Key search terms

The terms listed below are the core search terms that were used for EBSCOhost MEDLINE (searched 28th November 2018). These were combined with filters to identify guidelines, systematic reviews and primary care relevant literature in EBSCOhost MEDLINE. The strategy was adapted for The Cochrane Library databases. 

S3    S1 OR S2 
S2    AB ( diarrhea* or diarrhoea* ) OR TI ( diarrhea* or diarrhoea* ) 
S1    (MH "Diarrhea") 

Sources of guidelines

Sources of systematic reviews and meta-analyses

  • The Cochrane Library:
    • Systematic reviews
    • Protocols
    • Database of Abstracts of Reviews of Effects
  • Medline (with systematic review filter)
  • EMBASE (with systematic review filter)

Sources of health technology assessments and economic appraisals

Sources of randomized controlled trials

  • The Cochrane Library:
    • Central Register of Controlled Trials
  • Medline (with randomized controlled trial filter)
  • EMBASE (with randomized controlled trial filter)

Sources of evidence based reviews and evidence summaries

Sources of national policy

Patient experiences

Sources of medicines information

The following sources are used by CKS pharmacists and are not necessarily searched by CKS information specialists for all topics. Some of these resources are not freely available and require subscriptions to access content.

Stakeholder engagement

Our policy

The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:

  • Clinical accuracy.
  • Consistency with other providers of clinical knowledge for primary care.
  • Accuracy of implementation of national guidance (in particular NICE guidelines).
  • Usability.

Principles of the consultation process

  • The process is inclusive and any individual may participate.
  • To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.
  • Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.
  • Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.
  • External reviewers are not paid for commenting on the draft topics.
  • Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).
  • All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.
  • All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.

Stakeholders

  • Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the Getting involved section of the Clarity Informatics website.
  • Stakeholders identified from the following groups are invited to review draft topics:
    • Experts in the topic area.
    • Professional organizations and societies (for example, Royal Colleges).
    • Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.
    • Guideline development groups where the topic is an implementation of a guideline.
    • The British National Formulary team.
    • The editorial team that develop MeReC Publications.
  • Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.

Patient engagement

Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:

  • Topic selection
  • Scoping of topic
  • Selection of clinical scenarios
  • First draft internal review
  • Second draft internal review
  • External review
  • Final draft and pre-publication

Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.

Evidence exclusion criteria

Our policy

Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.

Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.

Standard exclusions for scoping literature:

  • Animal studies
  • Original research is not written in English

Possible exclusions for reviewed literature:

  • Sample size too small or study underpowered
  • Bias evident or promotional literature
  • Population not relevant
  • Intervention/treatment not relevant
  • Outcomes not relevant
  • Outcomes have no clear evidence of clinical effectiveness
  • Setting not relevant
  • Not relevant to UK
  • Incorrect study type
  • Review article
  • Duplicate reference

Organizational, behavioural and financial barriers

Our policy

The CKS literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.

  • Feasibility
    • Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.
  • Organizational and Financial Impact Analysis
  • Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.
    • Eligible population
    • Current interventions
    • Likely uptake of new intervention or recommendation
    • Cost of the current or new intervention mix
    • Impact on other costs
    • Condition-related costs
    • In-direct costs and service impacts
    • Time dependencies
  • Cost-effectiveness or cost-benefit analysis studies are identified where available. 

We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines. When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.

Declarations of interest

Our policy

Clarity Informatics requests that all those involved in the writing and reviewing of topics, and those involved in the external review process to declare any competing interests. Signed copies are securely held by Clarity Informatics and are available on request with the permission of the individual. A copy of the declaration of interest form which participants are asked to complete annually is also available on request. A brief outline of the declarations of interest policy is described here and full details of the policy is available on the Clarity Informatics website. Declarations of interests of the authors are not routinely published, however competing interests of all those involved in the topic update or development are listed below. Competing interests include:

  • Personal financial interests
  • Personal family interest
  • Personal non-financial interest
  • Non-personal financial gain or benefit

Although particular attention is given to interests that could result in financial gains or losses for the individual, competing interests may also arise from academic competition or for political, personal, religious, and reputational reasons. An individual is not obliged to seek out knowledge of work done for, or on behalf of, the healthcare industry within the departments for which they are responsible if they would not normally expect to be informed.

Who should declare competing interests?

Any individual (or organization) involved in developing, reviewing, or commenting on clinical content, particularly the recommendations should declare competing interests. This includes the authoring team members, expert advisers, external reviewers of draft topics, individuals providing feedback on published topics, and Editorial Steering Group members. Declarations of interest are completed annually for authoring team and editorial steering group members, and are completed at the start of the topic update and development process for external stakeholders.

Competing interests declared for this topic:

None.

References

  • Akhondi, H. and Simonsen, K.A. (2023) Bacterial Diarrhea. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [Free Full-text]
  • Arasaradnam, R.P., Brown, S. and Forbes, A. (2018) Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut 67(8), 1380-1399. [Abstract] [Free Full-text]
  • BMJ Best Practice (2023a) Assessment of acute diarrhoea. BMJ Publishing Group. http://bestpractice.bmj.com
  • BMJ Best Practice (2023b) Assessment of chronic diarrhoea. BMJ Publishing Group. http://bestpractice.bmj.com
  • BSG (2016) BSG guidance document on use of faecal calprotectin. British Society of Gastroenterology. http://www.bsg.org.uk [Free Full-text]
  • Bunn, D.K. and Hooper, L. (2019) Signs and Symptoms of Low-Intake Dehydration Do Not Work in Older Care Home Residents-DRIE Diagnostic Accuracy Study. Journal of the American Medical Directors Association 20(8), 963-970. [Abstract]
  • CDC (2023) Travelers’ Diarrhea. CDC Yellow Book — Preparing International Travelers. Centres for Disease Control. https://wwwnc.cdc.gov [Free Full-text]
  • Chapman, T.P., Chen, L.Y. and Leaver, L. (2015) Investigating young adults with chronic diarrhoea in primary care. British Medical Journal 350, h573. [Abstract]
  • Descoteaux-Friday, G.J. and Shrimanker, I. (2023) Chronic Diarrhea. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [Free Full-text]
  • Farthing, M., Feldman, R., Finch, R., et al. (1996) The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection. Journal of Infection 33(3), 143-152. [Abstract]
  • Ferris, A., Gaisinskaya, P. and Nandi, N. (2023) Approach to diarrhea. Primary Care 50(3), 447-459. [Abstract] [Free Full-text]
  • GBD 2016 Diarrhoeal Disease Collaborators (2018) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Disease 18(11), 1211-1228. [Free Full-text]
  • Gentile, N. and Yen, E.F. (2018) Prevalence, pathogenesis, diagnosis, and management of microscopic colitis. Gut and Liver 12(3), 227-235. [Abstract] [Free Full-text]
  • Hughes, L.E., Ford, C., Brookes, M.J. and Gama, R. (2021) Bile acid diarrhoea: Current and potential methods of diagnosis. Annals Clinical Biochemistry 581(1), 22-28. [Free Full-text]
  • John, J. and Lawton, M. D. (2021) Chronic diarrhoea. Clinical Medicine 21(4), 427-428. [Free Full-text]
  • Lacey, J., Corbett, J., Forni, L., et al. (2019) A multidisciplinary consensus on dehydration: definitions, diagnostic methods and clinical implications. Annals of Medicine 51(3-4), 232-251. [Free Full-text]
  • Nemeth, V. and Pfleghaar, N. (202) Diarrhea. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [Free Full-text]
  • NICE (2015a) Suspected cancer: recognition and referral. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • NICE (2015b) Coeliac disease: recognition, assessment and management. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • NICE (2016a) Coeliac disease. Quality standard [QS134]. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • NICE (2016b) Irritable bowel syndrome in adults. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • NICE (2016c) Suspected cancer. National Institute for Health and Care Excellence. https://www.nice.org.uk [Free Full-text]
  • NICE (2017) Irritable bowel syndrome in adults: diagnosis and management. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • NICE (2023) Suspected cancer: recognition and referral. National Institute for Health and Care Excellence. http://www.nice.org.uk [Free Full-text]
  • Shane, A.L., Mody, R.K., Crump, J.A., et al. (2017) 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases 65(12), e45-e80. [Abstract] [Free Full-text]
  • Tam, C.C., Rodrigues, L.C., Viviani, L., et al. (2012a) Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 61(1), 69-77. [Free Full-text]
  • Tam, C.C., Rodrigues, L.C., Viviani, L., et al. (2012b) Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. Gut 61(1), 69-77. [Abstract]
  • UKHSA (2023) Managing specific infectious diseases: A to Z. UK Health Security Agency. https://www.gov.uk [Free Full-text]
  • WHO (2017) Diarrhoeal disease. Fact sheet. World Health Organization. http://www.who.int [Free Full-text]
Change privacy settings